DOUBLE-BLIND LEVAMISOLE TRIAL IN RESECTABLE LUNG CANCER

The third interim analysis of a prospective double-blind placebo-controlled trial with levamisole as an adjunct to surgery in resectable primary lung carcinoma is reported. The data show that a beneficial effect is clearly present in patients who weigh 70 kg or less but not in others; therefore, it...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 1976-01, Vol.277 (1), p.260-268
Main Author: Amery, Willem K.
Format: Article
Language:English
Subjects:
Adult
Aged
Belgium
Chemical Phenomena
Chemistry
Clinical Trials as Topic
Female
Humans
Levamisole - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - surgery
Male
Middle Aged
Placebos
Prospective Studies
Skin Tests
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The third interim analysis of a prospective double-blind placebo-controlled trial with levamisole as an adjunct to surgery in resectable primary lung carcinoma is reported. The data show that a beneficial effect is clearly present in patients who weigh 70 kg or less but not in others; therefore, it would seem advisable to prescribe levamisole at a dosage of 2.5 mg/kg/day. In the adequately dosed patients, an almost complete elimination of distant metastases is found. The levamisole effect also seem more pronounced in patients who have a heavier tumor load at operation. The rationale for starting levamisole before surgery and for continuing thereafter is briefly discussed.
ISSN:0077-8923
1749-6632
DOI:10.1111/j.1749-6632.1976.tb41704.x